Skip to main
QURE

uniQure (QURE) Stock Forecast & Price Target

uniQure (QURE) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 36%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

uniQure NV demonstrates a positive outlook due to its advancing gene therapy pipeline, notably with AMT-130 for Huntington's disease and AMT-191 for Fabry disease, which are showing credible progress toward regulatory approval. The company’s financial metrics indicate increased investment in its operations, with SG&A expenses rising to $21.6 million, suggesting a commitment to growth and development. Furthermore, the enhancements to its asset portfolio and a strong balance sheet position uniQure favorably for strategic opportunities, reinforcing investor confidence in its multi-faceted approach to treating severe genetic diseases.

Bears say

uniQure NV faces significant financial challenges due to its status as a clinical-stage company that has yet to bring a revenue-generating product to market, resulting in continuous losses since its inception. Additionally, the company is vulnerable to market competition from both existing and emerging therapies that target similar indications, which can adversely affect its market penetration and pricing strategies. Furthermore, potential delays in clinical development, regulatory approvals, or commercialization timelines may prolong development periods and escalate associated costs, further straining the company's financial position.

uniQure (QURE) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 36% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About uniQure (QURE) Forecast

Analysts have given uniQure (QURE) a Buy based on their latest research and market trends.

According to 11 analysts, uniQure (QURE) has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

uniQure (QURE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.